Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 18 | 2025 | 1209 | 3.970 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 168 | 3.250 |
Why?
|
| Dyslipidemias | 5 | 2023 | 61 | 1.970 |
Why?
|
| Hypertension | 10 | 2026 | 1024 | 1.940 |
Why?
|
| Diabetes Mellitus | 8 | 2024 | 439 | 1.930 |
Why?
|
| Practice Guidelines as Topic | 10 | 2018 | 429 | 1.670 |
Why?
|
| Telemedicine | 2 | 2026 | 120 | 1.570 |
Why?
|
| Risk Assessment | 13 | 2025 | 1506 | 1.570 |
Why?
|
| Troponin T | 4 | 2019 | 98 | 1.540 |
Why?
|
| Heart Failure | 7 | 2024 | 780 | 1.510 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2019 | 10 | 1.490 |
Why?
|
| United States | 26 | 2025 | 4267 | 1.330 |
Why?
|
| Myocardial Infarction | 8 | 2024 | 515 | 1.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 364 | 1.200 |
Why?
|
| Middle Aged | 35 | 2025 | 12703 | 1.170 |
Why?
|
| Humans | 57 | 2026 | 34474 | 1.120 |
Why?
|
| Male | 44 | 2025 | 20697 | 1.110 |
Why?
|
| Cardiology | 4 | 2017 | 110 | 1.100 |
Why?
|
| American Heart Association | 4 | 2017 | 92 | 1.090 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 185 | 1.090 |
Why?
|
| Guideline Adherence | 7 | 2018 | 122 | 1.080 |
Why?
|
| Hospitalization | 4 | 2017 | 500 | 1.050 |
Why?
|
| Registries | 10 | 2019 | 328 | 1.030 |
Why?
|
| Atherosclerosis | 6 | 2022 | 837 | 1.030 |
Why?
|
| Hyperlipidemias | 2 | 2025 | 61 | 1.010 |
Why?
|
| Football | 4 | 2014 | 82 | 1.010 |
Why?
|
| Female | 40 | 2025 | 21490 | 1.000 |
Why?
|
| Retirement | 3 | 2014 | 13 | 0.960 |
Why?
|
| Primary Prevention | 1 | 2025 | 57 | 0.910 |
Why?
|
| Cognition | 2 | 2019 | 576 | 0.900 |
Why?
|
| Aged | 25 | 2025 | 10998 | 0.830 |
Why?
|
| Research Design | 1 | 2026 | 337 | 0.820 |
Why?
|
| Risk Factors | 21 | 2019 | 4136 | 0.820 |
Why?
|
| Retinal Diseases | 1 | 2024 | 26 | 0.810 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 129 | 0.790 |
Why?
|
| Stroke Volume | 2 | 2017 | 440 | 0.790 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 441 | 0.760 |
Why?
|
| Adult | 21 | 2025 | 10015 | 0.760 |
Why?
|
| Lipoprotein(a) | 2 | 2019 | 25 | 0.710 |
Why?
|
| Intermittent Claudication | 2 | 2018 | 11 | 0.700 |
Why?
|
| Health Status | 4 | 2017 | 411 | 0.700 |
Why?
|
| Cholesterol | 3 | 2017 | 273 | 0.670 |
Why?
|
| Coronary Disease | 3 | 2016 | 239 | 0.670 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 248 | 0.640 |
Why?
|
| Cognition Disorders | 2 | 2019 | 390 | 0.590 |
Why?
|
| Apolipoproteins B | 1 | 2019 | 49 | 0.590 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 89 | 0.590 |
Why?
|
| Obesity | 4 | 2023 | 1244 | 0.570 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2016 | 20 | 0.560 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 22 | 0.560 |
Why?
|
| Time Factors | 13 | 2019 | 2352 | 0.540 |
Why?
|
| Body Mass Index | 4 | 2025 | 953 | 0.520 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 107 | 0.510 |
Why?
|
| Hospital Costs | 1 | 2017 | 51 | 0.510 |
Why?
|
| Mortality | 1 | 2017 | 127 | 0.500 |
Why?
|
| Health Status Disparities | 1 | 2018 | 138 | 0.500 |
Why?
|
| Triglycerides | 1 | 2017 | 249 | 0.500 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 11 | 0.500 |
Why?
|
| Forecasting | 1 | 2017 | 153 | 0.500 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 63 | 0.500 |
Why?
|
| Peptide Fragments | 1 | 2019 | 429 | 0.490 |
Why?
|
| Blood Pressure | 5 | 2020 | 901 | 0.490 |
Why?
|
| Primary Health Care | 3 | 2025 | 240 | 0.480 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 70 | 0.480 |
Why?
|
| Inservice Training | 1 | 2016 | 13 | 0.480 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 72 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 87 | 0.460 |
Why?
|
| Prospective Studies | 9 | 2019 | 2461 | 0.460 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 58 | 0.460 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 6 | 0.460 |
Why?
|
| Exercise Therapy | 1 | 2018 | 283 | 0.460 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 14 | 0.460 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.460 |
Why?
|
| Diabetes Complications | 1 | 2016 | 189 | 0.450 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 74 | 0.450 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 138 | 0.440 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 210 | 0.440 |
Why?
|
| Waist Circumference | 1 | 2014 | 94 | 0.430 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 185 | 0.430 |
Why?
|
| Comorbidity | 7 | 2017 | 596 | 0.420 |
Why?
|
| Self Efficacy | 2 | 2025 | 79 | 0.420 |
Why?
|
| Occupations | 1 | 2014 | 10 | 0.420 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 193 | 0.420 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 287 | 0.420 |
Why?
|
| Neck | 1 | 2014 | 31 | 0.410 |
Why?
|
| Athletes | 1 | 2014 | 72 | 0.410 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1176 | 0.410 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 183 | 0.410 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2019 | 94 | 0.400 |
Why?
|
| Nepal | 4 | 2025 | 11 | 0.380 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3618 | 0.360 |
Why?
|
| Incidence | 5 | 2019 | 1288 | 0.360 |
Why?
|
| African Americans | 1 | 2018 | 1435 | 0.340 |
Why?
|
| Disease Management | 2 | 2025 | 134 | 0.330 |
Why?
|
| Lipids | 3 | 2017 | 267 | 0.320 |
Why?
|
| Cohort Studies | 5 | 2017 | 1910 | 0.310 |
Why?
|
| Prognosis | 4 | 2017 | 1603 | 0.310 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 14 | 0.310 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2366 | 0.310 |
Why?
|
| Calcinosis | 3 | 2014 | 150 | 0.300 |
Why?
|
| Stents | 3 | 2017 | 167 | 0.290 |
Why?
|
| Calcium | 3 | 2014 | 343 | 0.280 |
Why?
|
| Logistic Models | 6 | 2017 | 808 | 0.280 |
Why?
|
| Linear Models | 4 | 2017 | 464 | 0.280 |
Why?
|
| Prevalence | 6 | 2017 | 1034 | 0.270 |
Why?
|
| Focus Groups | 2 | 2025 | 125 | 0.270 |
Why?
|
| Quality of Life | 3 | 2018 | 1032 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 803 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 934 | 0.250 |
Why?
|
| Postprandial Period | 2 | 2016 | 11 | 0.240 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 260 | 0.240 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 304 | 0.240 |
Why?
|
| Rural Population | 2 | 2025 | 297 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 136 | 0.230 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 59 | 0.230 |
Why?
|
| Coronary Angiography | 3 | 2017 | 168 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1523 | 0.210 |
Why?
|
| Metals | 2 | 2017 | 20 | 0.210 |
Why?
|
| Health Personnel | 1 | 2025 | 131 | 0.210 |
Why?
|
| Stroke | 2 | 2024 | 700 | 0.210 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 9 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 168 | 0.200 |
Why?
|
| North Carolina | 3 | 2025 | 1612 | 0.200 |
Why?
|
| Southeastern United States | 1 | 2023 | 82 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 703 | 0.200 |
Why?
|
| Coronary Vessels | 2 | 2014 | 180 | 0.200 |
Why?
|
| Family Practice | 1 | 2023 | 49 | 0.200 |
Why?
|
| Universities | 1 | 2024 | 152 | 0.190 |
Why?
|
| Medical History Taking | 1 | 2022 | 41 | 0.190 |
Why?
|
| Medicare | 1 | 2024 | 217 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 1607 | 0.180 |
Why?
|
| Refugees | 1 | 2022 | 9 | 0.180 |
Why?
|
| India | 3 | 2016 | 65 | 0.180 |
Why?
|
| Odds Ratio | 4 | 2016 | 480 | 0.180 |
Why?
|
| Hemorrhage | 2 | 2019 | 109 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 4150 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 372 | 0.170 |
Why?
|
| Health Facilities | 1 | 2020 | 15 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 39 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2017 | 202 | 0.160 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 28 | 0.160 |
Why?
|
| Protein Precursors | 1 | 2019 | 27 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 18 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 35 | 0.150 |
Why?
|
| Models, Statistical | 2 | 2017 | 193 | 0.150 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 31 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 302 | 0.150 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 59 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 922 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 34 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2019 | 74 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 318 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 106 | 0.140 |
Why?
|
| Canada | 1 | 2018 | 69 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 612 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 194 | 0.130 |
Why?
|
| Coronary Restenosis | 2 | 2017 | 15 | 0.130 |
Why?
|
| Cause of Death | 1 | 2017 | 245 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2018 | 251 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 140 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 47 | 0.130 |
Why?
|
| Patient Preference | 1 | 2017 | 49 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 53 | 0.120 |
Why?
|
| Heterozygote | 1 | 2016 | 66 | 0.120 |
Why?
|
| Texas | 1 | 2016 | 40 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 55 | 0.120 |
Why?
|
| Transients and Migrants | 1 | 2019 | 304 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 67 | 0.120 |
Why?
|
| Veterans | 1 | 2016 | 73 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 70 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2017 | 597 | 0.120 |
Why?
|
| Developing Countries | 1 | 2016 | 60 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 801 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 22 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 138 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 141 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 755 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3812 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2016 | 113 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 131 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 323 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2016 | 160 | 0.110 |
Why?
|
| Alleles | 1 | 2015 | 257 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2015 | 168 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 99 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 378 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 565 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 925 | 0.110 |
Why?
|
| Anthropometry | 1 | 2014 | 88 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 24 | 0.110 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 61 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 378 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 33 | 0.100 |
Why?
|
| World Health Organization | 2 | 2025 | 17 | 0.100 |
Why?
|
| Apoptosis | 1 | 2015 | 400 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 349 | 0.100 |
Why?
|
| Mutation | 1 | 2015 | 529 | 0.100 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 2825 | 0.090 |
Why?
|
| Mass Screening | 1 | 2014 | 268 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 411 | 0.090 |
Why?
|
| Inflammation | 1 | 2014 | 557 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 544 | 0.080 |
Why?
|
| Thrombosis | 1 | 2011 | 88 | 0.080 |
Why?
|
| Kansas | 1 | 2025 | 8 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2025 | 108 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2017 | 116 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2025 | 529 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 194 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 17 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 200 | 0.050 |
Why?
|
| Bhutan | 1 | 2022 | 1 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 3799 | 0.040 |
Why?
|
| Public Sector | 1 | 2020 | 2 | 0.040 |
Why?
|
| Private Sector | 1 | 2020 | 9 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2020 | 7 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 35 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 163 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 202 | 0.040 |
Why?
|
| Urban Population | 1 | 2020 | 97 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 17 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 5 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 19 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2019 | 49 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 20 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 76 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 37 | 0.040 |
Why?
|
| Spain | 1 | 2017 | 3 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 207 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 60 | 0.030 |
Why?
|
| Missouri | 1 | 2017 | 21 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 43 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 51 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 633 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 62 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 188 | 0.030 |
Why?
|
| Patient Participation | 1 | 2017 | 93 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 129 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 291 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 143 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 61 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 230 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 29 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 45 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 44 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 108 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 100 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 656 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 583 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 259 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 593 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 17 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2012 | 10 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1261 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 849 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 155 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 75 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 50 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 34 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 73 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 295 | 0.020 |
Why?
|